Figure 5 | Scientific Reports

Figure 5

From: Novel intranasal vaccine targeting SARS-CoV-2 receptor binding domain to mucosal microfold cells and adjuvanted with TLR3 agonist Riboxxim™ elicits strong antibody and T-cell responses in mice

Figure 5

Bivalent SARS-CoV-2 RBD-cCPE/Influenza H1-HA1-cCPE vaccine induces IgG antibody responses in NALF, BALF and serum against RBD and spike of SARS-CoV-2 wildtype and variants. Mice were prime-boost immunized intranasally (days 0 and 21) with bivalent SARS-CoV-2 RBD-cCPE/influenza H1-HA1-cCPE vaccine, adjuvanted with Riboxxim. NALF, BALF and sera were obtained on day 28, 1 week after the boost, diluted in fourfold steps, and assayed for IgG antibodies in Luminex with recombinant monomeric RBD (Wuhan-Hu-1/wildtype, or point mutations N501Y, or E484K), or recombinant trimeric spike protein (Wuhan-Hu-1, B.1.1.7, B.1.351), or recombinant monomeric H1-HA1 (A/swine/Guangxi/3843/2011(H1N1), respectively. Endpoint titers (NALF, BALF) or EC50 (serum) were calculated where applicable. Log10 of endpoint titers or EC50 were plotted with geometric mean ± geometric SD.

Back to article page